move california

Zogenix. Inc. a privately held neuroscience-focused specialty pharmaceutical company announced today that Stephen J. Peroutka. M. D.. Ph. D has joined the company in the role of Chief Medical Officer. Dr. Peroutka is a neurologist and pharmacologist whose research and professional experience in neuroscience spans twenty-five years. Dr. Peroutka received his M. D and Ph. D degrees in 1979 and 1980 respectively from the Johns Hopkins University School of Medicine. After completing an internship at Stanford in 1981 and a residency at Johns Hopkins Hospital he was an Assistant Professor of Neurology and Pharmacology at Stanford from 1984-1990 and was Chief. Neurology Service at the Palo Alto VA Hospital from 1988-1990. In 1990 he joined Genentech. Inc where he established the Department of Neuroscience and became its first Director in 1991. In 1993 he founded Spectra Biomedical. Inc. an association genetics company focused on migraine. In June. 1997. Spectra Biomedical. Inc was acquired by Glaxo Wellcome Inc. Subsequently he has been an independent consultant to the pharmaceutical and biotechnology industries. He was Chief Medical Officer at Collabra Pharma in 2000-2001. Vice President of Clinical Research at Deltagen. Inc in 2001-2002 and President and CEO of Synergia Pharma. Inc from 2003-2005. Most recently he was the Franchise Development Leader for Pain at Johnson & Johnson. “Having Steve join our management team is highly significant for Zogenix,” said Stephen Farr. Ph. D.. President and COO. “His scientific clinical and business experience particularly in the areas of migraine and hurt will be invaluable as we continue to build our pipeline and move into the commercialization phase with our first product sumatriptan Intraject®.” About Zogenix. Inc. Zogenix. Inc. with offices in Emeryville and San Diego. CA is a private specialty pharmaceutical company focused on the development and commercialization of medicines to treat neuroscience disorders and pain. The company's initial focus is the completion of the late-stage development and commercialization of sumatriptan Intraject – a needle-free single-use disposable and easy-to-use subcutaneous delivery system for sumatriptan that will compete in the $2.7 billion triptan segment of the migraine market. The company also plans to authorise the patented Intraject drug delivery system to other companies. For additional information tour.

Forex Groups - Tips on Trading

Related article:
http://www.freshnews.com/news/tech-people-move/article_40656.html

comments | Add comment | Report as Spam

Zogenix. Inc. a privately held neuroscience-focused specialty pharmaceutical company announced today that Stephen J. Peroutka. M. D.. Ph. D has joined the company in the role of Chief Medical Officer. Dr. Peroutka is a neurologist and pharmacologist whose research and professional experience in neuroscience spans twenty-five years. Dr. Peroutka received his M. D and Ph. D degrees in 1979 and 1980 respectively from the Johns Hopkins University School of Medicine. After completing an internship at Stanford in 1981 and a residency at Johns Hopkins Hospital he was an Assistant Professor of Neurology and Pharmacology at Stanford from 1984-1990 and was Chief. Neurology Service at the Palo Alto VA Hospital from 1988-1990. In 1990 he joined Genentech. Inc where he established the Department of Neuroscience and became its first Director in 1991. In 1993 he founded Spectra Biomedical. Inc. an association genetics company focused on migraine. In June. 1997. Spectra Biomedical. Inc was acquired by Glaxo Wellcome Inc. Subsequently he has been an independent consultant to the pharmaceutical and biotechnology industries. He was Chief Medical Officer at Collabra Pharma in 2000-2001. Vice President of Clinical Research at Deltagen. Inc in 2001-2002 and President and CEO of Synergia Pharma. Inc from 2003-2005. Most recently he was the Franchise Development Leader for Pain at Johnson & Johnson. “Having Steve join our management team is highly significant for Zogenix,” said Stephen Farr. Ph. D.. President and COO. “His scientific clinical and business experience particularly in the areas of migraine and pain will be invaluable as we act to build our pipeline and move into the commercialization phase with our first product sumatriptan Intraject®.” About Zogenix. Inc. Zogenix. Inc. with offices in Emeryville and San Diego. CA is a private specialty pharmaceutical company focused on the development and commercialization of medicines to treat neuroscience disorders and pain. The affiliate's initial focus is the completion of the late-stage development and commercialization of sumatriptan Intraject – a needle-free single-use disposable and easy-to-use subcutaneous delivery system for sumatriptan that will compete in the $2.7 billion triptan segment of the migraine market. The company also plans to license the patented Intraject drug delivery system to other companies. For additional information visit.

Forex Groups - Tips on Trading

Related article:
http://www.freshnews.com/news/tech-people-move/article_40656.html

comments | Add comment | Report as Spam

Zogenix. Inc. a privately held neuroscience-focused specialty pharmaceutical company announced today that Stephen J. Peroutka. M. D.. Ph. D has joined the company in the role of Chief Medical Officer. Dr. Peroutka is a neurologist and pharmacologist whose research and professional experience in neuroscience spans twenty-five years. Dr. Peroutka received his M. D and Ph. D degrees in 1979 and 1980 respectively from the Johns Hopkins University educate of Medicine. After completing an internship at Stanford in 1981 and a residency at Johns Hopkins Hospital he was an Assistant Professor of Neurology and Pharmacology at Stanford from 1984-1990 and was Chief. Neurology Service at the Palo Alto VA Hospital from 1988-1990. In 1990 he joined Genentech. Inc where he established the Department of Neuroscience and became its first Director in 1991. In 1993 he founded Spectra Biomedical. Inc. an association genetics company focused on migraine. In June. 1997. Spectra Biomedical. Inc was acquired by Glaxo Wellcome Inc. Subsequently he has been an independent consultant to the pharmaceutical and biotechnology industries. He was Chief Medical Officer at Collabra Pharma in 2000-2001. Vice President of Clinical Research at Deltagen. Inc in 2001-2002 and President and CEO of Synergia Pharma. Inc from 2003-2005. Most recently he was the Franchise Development Leader for Pain at Johnson & Johnson. “Having Steve join our management team is highly significant for Zogenix,” said Stephen Farr. Ph. D.. President and COO. “His scientific clinical and business experience particularly in the areas of migraine and hurt ordain be invaluable as we continue to build our pipeline and move into the commercialization arrange with our first product sumatriptan Intraject®.” About Zogenix. Inc. Zogenix. Inc. with offices in Emeryville and San Diego. CA is a private specialty pharmaceutical company focused on the development and commercialization of medicines to treat neuroscience disorders and pain. The company's initial focus is the completion of the late-stage development and commercialization of sumatriptan Intraject – a needle-free single-use disposable and easy-to-use subcutaneous delivery system for sumatriptan that will compete in the $2.7 billion triptan segment of the migraine market. The company also plans to license the patented Intraject drug delivery system to other companies. For additional information visit.

Forex Groups - Tips on Trading

Related article:
http://www.freshnews.com/news/tech-people-move/article_40656.html

comments | Add comment | Report as Spam

Genesis Microchip Inc. (Nasdaq: GNSS) a world leader in the development of image and video processing technologies for flat-panel TVs monitors and other consumer show products today announced that it has named heap Martig to the position of Chief Financial command and Senior Vice President. Finance effective November 5. 2007. Mr. Martig brings more than twenty years of finance accounting and management experience to Genesis. In his new position he will report directly to Elie Antoun. President and Chief Executive Officer of Genesis. “We are very pleased to accept Rick to the Genesis aggroup and be forward to his immediate contributions to the affiliate’s continued growth,” said Elie Antoun president and CEO. Genesis Microchip. “Rick is a seasoned technology industry veteran with many years of direct financial expertise in operations control financial planning and analysis treasury and compliance functions. He also possesses a proven ability to back up bring about a successful public company.” “I am excited to be joining the Genesis team,” said Rick Martig. “This is an outstanding company with industry leading technology strong leadership and a dedicated employee base. I look forward to working with Elie and the management aggroup at Genesis to execute on the affiliate’s initiatives and its goal of returning to long-term sustainable profitability.” Prior to joining Genesis. Mr. Martig spent twelve years at Xilinx. Inc. (Nasdaq: XLNX) a worldwide leader in field programmable furnish arrange (FPGA) solutions. Most recently at Xilinx he served as Senior Director of Corporate pay and managed the Company’s worldwide accounting operations in San Jose. Dublin and Singapore. In this role he was responsible for corporate accounting financial planning and analysis and external reporting. Mr. Martig also led the implementation of SOX 404 and the creation of an internal compliance organization. From 1997 to 2003 at Xilinx. Mr. Martig was Business Unit Operations Controller. Prior to Xilinx. Mr. Martig worked from 1990 to 1995 at Spectra Physics Lasers where he served in various roles including Plant Controller and Treasury Manager. Previously. Mr. Martig was a command Accounting Manager at Bonsu – Microamerica from 1985 to 1990. He is a have of the University of Santa Clara with a BS degree in finance and holds an MBA from St. Mary’s College. About Genesis Microchip Genesis Microchip Inc. (Nasdaq: GNSS) is a leading provider of image and video processing systems enabling superior conceive of quality in flat-panel TVs and a variety of consumer and PC-display products. Featuring Genesis Display Perfection® technologies and Emmy award-winning Faroudja® video technologies. Genesis system-on-a-chip solutions are used worldwide by display manufacturers to produce visibly exceed images across a broad arrange of devices including flat-panel displays digital TVs projectors. A/V receivers and DVD players/recorders. Genesis is also the primary driver of the DisplayPort digital interface standard which enables a common change state obtain royalty free scalable interface between any flat adorn show and video or data source. In addition to DisplayPort technology the Genesis technology portfolio features analog and mixed signal system-on-a-chip design. DCDi® by Faroudja deinterlacing. TrueLife™ video enhancement. IntelliComb™ video decoding and includes over 210 patents. Founded in 1987. Genesis supports its leading brand-name customers with offices in the U. S.. Canada. India. Taiwan. South Korea. China. Japan and Singapore. For more information about Genesis Microchip Inc or Genesis Display Perfection technologies gratify visit.

Forex Groups - Tips on Trading

Related article:
http://www.freshnews.com/news/tech-people-move/article_40664.html

comments | Add comment | Report as Spam

Genesis Microchip Inc. (Nasdaq: GNSS) a world leader in the development of image and video processing technologies for flat-panel TVs monitors and other consumer display products today announced that it has named Rick Martig to the position of Chief Financial Officer and Senior Vice President. pay effective November 5. 2007. Mr. Martig brings more than twenty years of pay accounting and management experience to Genesis. In his new position he will report directly to Elie Antoun. President and Chief Executive command of Genesis. “We are very pleased to welcome heap to the Genesis team and look forward to his immediate contributions to the Company’s continued growth,” said Elie Antoun president and CEO. Genesis Microchip. “Rick is a seasoned technology industry veteran with many years of enjoin financial expertise in operations control financial planning and analysis treasury and compliance functions. He also possesses a proven ability to help bring about a successful public company.” “I am excited to be joining the Genesis team,” said heap Martig. “This is an outstanding affiliate with industry leading technology strong leadership and a dedicated employee locate. I look forward to working with Elie and the management aggroup at Genesis to execute on the company’s initiatives and its goal of returning to long-term sustainable profitability.” Prior to joining Genesis. Mr. Martig spent twelve years at Xilinx. Inc. (Nasdaq: XLNX) a worldwide leader in field programmable furnish arrange (FPGA) solutions. Most recently at Xilinx he served as Senior Director of Corporate Finance and managed the affiliate’s worldwide accounting operations in San Jose. Dublin and Singapore. In this role he was responsible for corporate accounting financial planning and analysis and external reporting. Mr. Martig also led the implementation of SOX 404 and the creation of an internal compliance organization. From 1997 to 2003 at Xilinx. Mr. Martig was Business Unit Operations Controller. Prior to Xilinx. Mr. Martig worked from 1990 to 1995 at Spectra Physics Lasers where he served in various roles including Plant Controller and Treasury Manager. Previously. Mr. Martig was a command Accounting Manager at Bonsu – Microamerica from 1985 to 1990. He is a graduate of the University of Santa Clara with a BS degree in pay and holds an MBA from St. Mary’s College. About Genesis Microchip Genesis Microchip Inc. (Nasdaq: GNSS) is a leading provider of image and video processing systems enabling superior picture quality in flat-panel TVs and a variety of consumer and PC-display products. Featuring Genesis show Perfection® technologies and Emmy award-winning Faroudja® video technologies. Genesis system-on-a-chip solutions are used worldwide by display manufacturers to produce visibly better images across a broad array of devices including flat-panel displays digital TVs projectors. A/V receivers and DVD players/recorders. Genesis is also the primary driver of the DisplayPort digital interface standard which enables a common open obtain royalty remove scalable interface between any flat panel show and video or data obtain. In addition to DisplayPort technology the Genesis technology portfolio features analog and mixed signal system-on-a-chip design. DCDi® by Faroudja deinterlacing. TrueLife™ video enhancement. IntelliComb™ video decoding and includes over 210 patents. Founded in 1987. Genesis supports its leading brand-name customers with offices in the U. S.. Canada. India. Taiwan. South Korea. China. Japan and Singapore. For more information about Genesis Microchip Inc or Genesis Display Perfection technologies please tour.

Forex Groups - Tips on Trading

Related article:
http://www.freshnews.com/news/tech-people-move/article_40664.html

comments | Add comment | Report as Spam

Genesis Microchip Inc. (Nasdaq: GNSS) a world leader in the development of visualise and video processing technologies for flat-panel TVs monitors and other consumer display products today announced that it has named Rick Martig to the lay of Chief Financial Officer and Senior Vice President. pay effective November 5. 2007. Mr. Martig brings more than twenty years of finance accounting and management experience to Genesis. In his new position he ordain report directly to Elie Antoun. President and Chief Executive Officer of Genesis. “We are very pleased to accept Rick to the Genesis team and be forward to his immediate contributions to the Company’s continued growth,” said Elie Antoun president and CEO. Genesis Microchip. “heap is a seasoned technology industry veteran with many years of direct financial expertise in operations hold back financial planning and analysis treasury and compliance functions. He also possesses a proven ability to help lead a successful public company.” “I am excited to be joining the Genesis team,” said Rick Martig. “This is an outstanding company with industry leading technology strong leadership and a dedicated employee base. I be send to working with Elie and the management team at Genesis to kill on the company’s initiatives and its goal of returning to long-term sustainable profitability.” Prior to joining Genesis. Mr. Martig spent twelve years at Xilinx. Inc. (Nasdaq: XLNX) a worldwide leader in field programmable gate array (FPGA) solutions. Most recently at Xilinx he served as Senior Director of Corporate pay and managed the Company’s worldwide accounting operations in San Jose. Dublin and Singapore. In this role he was responsible for corporate accounting financial planning and analysis and external reporting. Mr. Martig also led the implementation of SOX 404 and the creation of an internal compliance organization. From 1997 to 2003 at Xilinx. Mr. Martig was Business Unit Operations Controller. Prior to Xilinx. Mr. Martig worked from 1990 to 1995 at Spectra Physics Lasers where he served in various roles including lay Controller and Treasury Manager. Previously. Mr. Martig was a General Accounting Manager at Bonsu – Microamerica from 1985 to 1990. He is a graduate of the University of Santa Clara with a BS degree in finance and holds an MBA from St. Mary’s College. About Genesis Microchip Genesis Microchip Inc. (Nasdaq: GNSS) is a leading provider of image and video processing systems enabling superior conceive of quality in flat-panel TVs and a variety of consumer and PC-display products. Featuring Genesis Display Perfection® technologies and Emmy award-winning Faroudja® video technologies. Genesis system-on-a-chip solutions are used worldwide by show manufacturers to produce visibly better images across a broad array of devices including flat-panel displays digital TVs projectors. A/V receivers and DVD players/recorders. Genesis is also the primary driver of the DisplayPort digital interface standard which enables a common open obtain royalty free scalable interface between any flat adorn display and video or data source. In addition to DisplayPort technology the Genesis technology portfolio features analog and mixed communicate system-on-a-chip create by mental act. DCDi® by Faroudja deinterlacing. TrueLife™ video enhancement. IntelliComb™ video decoding and includes over 210 patents. Founded in 1987. Genesis supports its leading brand-name customers with offices in the U. S.. Canada. India. Taiwan. South Korea. China. Japan and Singapore. For more information about Genesis Microchip Inc or Genesis show Perfection technologies gratify visit.

Forex Groups - Tips on Trading

Related article:
http://www.freshnews.com/news/tech-people-move/article_40664.html

comments | Add comment | Report as Spam

Innovative Card Technologies. Inc. (NASDAQ:INVC) developers of the breakthrough ICT DisplayCard security device for e-banking e-commerce and data access today announced that Charles Caporale has joined the company as Chief Financial Officer effective October 29. 2007. Caporale replaces Bennet P. Tchaikovsky who will serve as consultant to Innovative Card Technologies during the transition. A seasoned CFO. Caporale comes to InCard most recently from New Horizons Computer Learning Centers where he worked alongside Steven R. Delcarson who was recently appointed Chief Executive Officer of Innovative Card Technologies. Caporale served as Senior Vice President and CFO of New Horizons from February 2006 until August of this year. “Cap brings established talent and skills in both finance and business leadership and I am glad to be working with him again. I am confident that his financial leadership skills will be a valuable contribution across departments,” said Delcarson. “I thank Bennet for his three plus years of service with the company and appreciate his support during the convert.” Caporale’s undergo includes serving as an independent financial and accounting consultant for clients in Southern California. He also served as Vice President. Chief Financial Officer. Treasurer and Secretary of Women First Healthcare from September 2000 to October 2003 and as Senior Vice President. Chief Financial command and Treasurer of The Centris Group. Inc from July 1997 until April 2000. Caporale holds a B. B. A in accounting from Pace University. “I am thrilled to again be working alongside Steve and to be a part of the forward-thinking management team that is bringing a revolutionary new technology display-bearing cards first to market,” said Caporale. “I am eager to lend my expertise to the company during this exciting time of early merchandise adoption of this vitally important new security device.” About Innovative Card Technologies Innovative separate Technologies (NASDAQ: INVC) was founded in 1993 to add functionalities to payment cards. InCard’s suite of ICT DisplayCards alter dual-factor authentication in a convenient card form. The cards can be configured to offer RFID physical find or payment capabilities and feature a screen powered by an integrated battery circuit and switch. This screen displays a one-time password to affirm the presence of the separate during online and express transactions or data systems login. Www incardtech com.

Forex Groups - Tips on Trading

Related article:
http://www.freshnews.com/news/tech-people-move/article_40610.html

comments | Add comment | Report as Spam

Amylin Pharmaceuticals. Inc. (NASDAQ:AMLN) today announced that Adrian Adams has been elected to the affiliate's Board of Directors effective immediately. "We are very pleased to accept Adrian to the Amylin come in," said Daniel M. Bradbury. President and CEO of Amylin Pharmaceuticals. "His international experience as a highly innovative strategic business leader combined with a bring in record of building organizations and delivering optimum results ordain compound our come in's depth of experience." Mr. Adams currently serves as President and CEO of Sepracor. Inc. Prior to this he was President and Chief Executive command of Kos Pharmaceuticals from 2002 until the acquisition of the affiliate by Abbott Laboratories in December 2006. Mr. Adams has over 30 years of experience in both specialty and large pharmaceutical organizations that in addition to Sepracor and Kos included careers with ICI. SmithKline Beecham and Novartis and involved bring home the bacon and product launches in most therapeutic areas. Mr. Adams has a broad accent encompassing research and development sales international and national product marketing business development and extensive general management undergo. He is a graduate of Manchester University in the United Kingdom with a live of Science degree. In addition to serving on the Amylin come in. Mr. Adams is actively involved as a board member of PhRMA (Pharmaceutical Research and Manufacturer of America). About Amylin Amylin Pharmaceuticals. Inc is a biopharmaceutical company committed to improving lives through the discovery development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes. SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities supplement the company's expertise in metabolism to develop potential therapies to interact diabetes and obesity. Amylin is headquartered in San Diego. California with over 1,800 employees nationwide. Further information on Amylin Pharmaceuticals is available at /.

Forex Groups - Tips on Trading

Related article:
http://www.freshnews.com/news/tech-people-move/article_40595.html

comments | Add comment | Report as Spam

Amylin Pharmaceuticals. Inc. (NASDAQ:AMLN) today announced that Adrian Adams has been elected to the company's come in of Directors effective immediately. "We are very pleased to accept Adrian to the Amylin Board," said Daniel M. Bradbury. President and CEO of Amylin Pharmaceuticals. "His international undergo as a highly innovative strategic business leader combined with a track record of building organizations and delivering optimum results will enhance our come in's depth of experience." Mr. Adams currently serves as President and CEO of Sepracor. Inc. Prior to this he was President and Chief Executive Officer of Kos Pharmaceuticals from 2002 until the acquisition of the company by Abbott Laboratories in December 2006. Mr. Adams has over 30 years of undergo in both specialty and large pharmaceutical organizations that in addition to Sepracor and Kos included careers with ICI. SmithKline Beecham and Novartis and involved bring home the bacon and product launches in most therapeutic areas. Mr. Adams has a broad accent encompassing research and development sales international and national product marketing business development and extensive general management experience. He is a have of Manchester University in the United Kingdom with a Bachelor of Science degree. In addition to serving on the Amylin Board. Mr. Adams is actively involved as a board member of PhRMA (Pharmaceutical Research and Manufacturer of America). About Amylin Amylin Pharmaceuticals. Inc is a biopharmaceutical company committed to improving lives through the discovery development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes. SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's investigate and development activities leverage the affiliate's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego. California with over 1,800 employees nationwide. advance information on Amylin Pharmaceuticals is available at /.

Forex Groups - Tips on Trading

Related article:
http://www.freshnews.com/news/tech-people-move/article_40595.html

comments | Add comment | Report as Spam

Amylin Pharmaceuticals. Inc. (NASDAQ:AMLN) today announced that Adrian Adams has been elected to the company's Board of Directors effective immediately. "We are very pleased to welcome Adrian to the Amylin Board," said Daniel M. Bradbury. President and CEO of Amylin Pharmaceuticals. "His international undergo as a highly innovative strategic business leader combined with a bring in record of building organizations and delivering optimum results ordain compound our come in's depth of undergo." Mr. Adams currently serves as President and CEO of Sepracor. Inc. Prior to this he was President and Chief Executive command of Kos Pharmaceuticals from 2002 until the acquisition of the company by Abbott Laboratories in December 2006. Mr. Adams has over 30 years of undergo in both specialty and large pharmaceutical organizations that in addition to Sepracor and Kos included careers with ICI. SmithKline Beecham and Novartis and involved work and product launches in most therapeutic areas. Mr. Adams has a broad background encompassing research and development sales international and national product marketing business development and extensive command management undergo. He is a have of Manchester University in the United Kingdom with a Bachelor of Science degree. In addition to serving on the Amylin come in. Mr. Adams is actively involved as a come in member of PhRMA (Pharmaceutical investigate and Manufacturer of America). About Amylin Amylin Pharmaceuticals. Inc is a biopharmaceutical affiliate committed to improving lives through the discovery development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes. SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to interact diabetes and obesity. Amylin is headquartered in San Diego. California with over 1,800 employees nationwide. advance information on Amylin Pharmaceuticals is available at /.

Forex Groups - Tips on Trading

Related article:
http://www.freshnews.com/news/tech-people-move/article_40595.html

comments | Add comment | Report as Spam